1999 Year in Review...News regarding Multiple Sclerosis

Oct 15 99 Copaxone and Betaseron Reduce Relapse Rate
Copaxone and Betaseron significantly reduced the incidence of relapses in patients with relapsing-remitting multiple sclerosis (MS).

Oct 07 99 New Treatment For Multiple Sclerosis
A plasma exchange procedure developed by physicians at Mayo Clinic, Rochester, MN, improved symptoms such as paralysis and loss of speech for 42 percent of patients with multiple sclerosis who had experienced flare-ups.

Sep 21 99 Washington DC Voted in Favor of Medical Marijuana
Residents of the nation's capital overwhelmingly voted to legalize marijuana use for medical purposes, according to year-old ballot results released for the first time on Monday after months of controversy.

Sep 17 99 New Treatment Options for Multiple Sclerosis
Mayo Clinic neurologists today reported the results of a new treatment option that was effective in over 40 percent of patients with severe attacks of multiple sclerosis and related diseases that cause inflammation and myelin destruction in the brain and spinal cord.

Sep 14 99 Berlex Halts Betaseron Study
Berlex Laboratories, the Montville, New Jersey-based unit of Germany's Schering AG, said on Monday that it would stop its ongoing US study of interferon beta 1-b (Betaseron) for treatment of secondary progressive multiple sclerosis, based on the recommendation of the Independent Monitoring Board.

Sep 13 99 Multiple Sclerosis Progresses Despite Suppression of Inflammation
The clinical course of multiple sclerosis ultimately involves axon degeneration which is triggered by inflammation but is not dependent on a continued inflammatory process.

Sep 01 99 Fight Vaccine Fears With Experts' Reports
Physicians disturbed by growing public backlash over real and imagined vaccine side effects should try not to take it personally

Aug 24 99 MS Survival Better When Optic Neuritis Is The Presenting Manifestation
Overall, multiple sclerosis (MS) patients with optic neuritis as the presenting manifestation of the disease appear to have a more favorable prognosis than MS patients with other onset manifestations, Danish researchers report

Aug 04 99 Hepatitis B Vaccination Should Be Avoided in Patients With Risk of CNS Disease
French researchers report eight cases in which patients developed central nervous system inflammation and demyelinating disease less than 10 weeks after receiving a hepatitis B vaccination.

Jul 20 99 Immunex Gets Word of Priority Review of Expanded Indication For Mitoxantrone
Immunex Corp. said on Monday that the US Food and Drug Administration will accelerate its review of the drug manufacturer's application to use mitoxantrone (Novantrone) to treat certain types of multiple sclerosis.

Jul 19 99 Prevalence of C. Pneumoniae in CSF High in Patients With Multiple Sclerosis
Vanderbilt clinicians report an excess prevalence of Chlamydia pneumoniae in the cerebral spinal fluid of patients with multiple sclerosis (MS).

May 20 99 Pneumonia Infection Linked To Multiple Sclerosis
A pneumonia-causing organism may trigger multiple sclerosis, according to a Tennessee researcher

Apr 23 99 Pneumonia May Play Role in Development of MS
An agent that causes respiratory tract infections such as community-acquired pneumonia, called Chlamydia pneumoniae, may be a factor in the development of multiple sclerosis (MS) in some patients.

Apr 20 99 Proteins May Inhibit the Development of Multiple Sclerosis
Treatment with portions of proteins from certain viruses and bacteria can inhibit the development of a multiple sclerosis-like autoimmune disease in susceptible mice, according to a new study by researchers.

Mar 03 99 No Causal Association Between Hepatitis B Vaccine And MS
The available evidence does not demonstrate a causal association between hepatitis B vaccination and CNS demyelinating diseases such as multiple sclerosis (MS).

Feb 27 99 Multiple Sclerosis Drugs Have A High Cost/QALY
Using the results of major trials, this report compares 4 products available for the treatment of MS: 'Avonex' [interferon-beta-1a], 'Rebif' [interferon-beta-1a], 'Betaseron' [interferon-beta-1b] and 'Copaxone' [glatiramer acetate].

Jan 21 99 Benefits of Physical Therapy Last After MS Patients Return Home
Hospital physical rehabilitation programs have a positive effect on multiple sclerosis patients that lasts after they return home